Targeted Therapy Evolution: From Kinase Inhibitors to Protein Degraders

This narrative review maps the full arc of targeted oncology drug development, giving pharmacists a mechanistic framework for counseling on emerging protein degraders and interpreting biomarker-driven regimens.

PROTACvepdegestranttargeted protein degradationsmall molecule inhibitorsmonoclonal antibodiesmolecular gluesSERDkinase inhibitorsCRISPRepigenetic therapyprecision oncologynarrative reviewdrug development Oncology Pharmacy

Background Information

Targeted cancer therapies revolutionize personalized oncology treatment.

Targeted cancer therapies offer a personalized approach to treatment, enhancing efficacy while minimizing side effects compared to traditional chemotherapy. The review highlights the evolution of targeted therapies and the development of technologies like PROTACs and CRISPR/Cas9, facing challenges such as therapeutic resistance. Impacts drug development, emphasizing challenges with 'undruggable' proteins and resistance, relevant to designing future oncology treatments. Targeted therapies redefine cancer treatment, presenting opportunities and challenges for oncology pharmacy.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Wang Y, Tang SC

Citation: Wang Y, Tang SC Targeted cancer therapy: A comprehensive review of strategies in drug development. Critical reviews in oncology/hematology. 2026;222:105303. doi:10.1016/j.critrevonc.2026.105303

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →